Welcome to our dedicated page for Emergent BioSolutions SEC filings (Ticker: EBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Emergent BioSolutions filings document an operating public-health company with NYSE-listed common stock under the symbol EBS. Its Form 8-K reports cover financial results, investor presentations, Regulation FD materials, debt prepayments, credit agreements, and other capital-structure events tied to its term loan and asset-based revolving facility.
Proxy and annual-meeting filings describe board elections, director appointments, committee service, auditor ratification, executive compensation, equity awards, and stockholder voting results. The filing record also captures governance disclosures for a company supplying NARCAN® Nasal Spray, ACAM2000®, and other medical countermeasure and bioservices products.
Emergent BioSolutions Inc. reported a routine insider equity transaction by its EVP and Chief Financial Officer, Richard S. Lindahl. On the reported date, 683 shares of common stock were disposed of at $8.15 per share to cover tax withholding tied to the vesting and settlement of restricted stock units. After this tax-withholding disposition, Lindahl directly owned 239,017 shares of Emergent BioSolutions common stock.
Emergent BioSolutions EVP Coleen Glessner reported a small share disposition related to taxes. On the vesting of restricted stock units, 313 shares of common stock were withheld at $8.15 per share to cover tax obligations. After this tax-withholding disposition, she directly owns 112,307 common shares.
Emergent BioSolutions Inc. has appointed John D. Fowler, Jr. as a Class II director effective March 1, 2026, with his initial term running until the 2026 annual stockholders meeting. He is considered an independent director and will serve on the Board’s Audit and Finance Committee.
Fowler will receive an initial restricted stock unit grant valued at $270,000, vesting in three equal annual installments, plus an annual cash retainer of $70,000 for Board service and $15,000 for committee service. He will also be eligible for an annual equity award valued at $270,000, split 75% into restricted stock units and 25% into options, subject to proration in his first year. The company highlighted his more than three decades of experience across healthcare and financial services.
Emergent BioSolutions is a global life sciences company focused on preparedness and response for public health threats, including smallpox, anthrax, Ebola and opioid overdoses. It operates commercial naloxone products, government-focused medical countermeasures and a smaller bioservices operation.
In 2025 the company advanced a multi-year turnaround, closing or selling several manufacturing sites, de-emphasizing services, and concentrating on core products. It completed the $36.5 million sale of its Bayview facility while retaining access, secured multiple BARDA and U.S. Department of War contracts for vaccines and therapeutics, expanded naloxone offerings by acquiring North American rights to KLOXXADO, received $80 million in Bavarian Nordic milestones, and combined a $100 million term-loan prepayment with board-authorized share and debt repurchase programs of up to $50 million in equity and $30 million of 2028 notes.
Emergent BioSolutions reported a major earnings turnaround for 2025 despite lower sales. Total revenues fell to $742.9M from $1,043.6M, driven largely by a $172.8M drop in naloxone revenue to $226.1M, while MCM product revenues declined more modestly to $456.7M.
The company moved from a net loss of $190.6M in 2024 to net income of $52.6M in 2025, with adjusted net income of $86.8M and adjusted EBITDA rising to $205.0M. Gross margin improved to 45%, and adjusted gross margin to 54%, reflecting restructuring benefits and a richer mix of higher-margin MCM products. Operating cash flow increased to $170.6M, enabling $110M of debt repayment and reducing net leverage to 1.9x.
For 2026, management guides total revenues of $720–$760M, expects a GAAP net loss of $30–$10M, and targets adjusted EBITDA of $135–$155M with adjusted gross margin of 45–47%. The outlook assumes flat-to-slightly down MCM revenues with meaningful international contribution and flat-to-slightly up commercial revenues, while the company continues buybacks under a new $50M share repurchase authorization.
Emergent BioSolutions Inc. senior vice president and general counsel Jessica Perl reported an automatic share withholding related to equity compensation. On February 9, 2026, 918 shares of common stock were withheld at $11.03 per share to pay taxes on vesting restricted stock units. After this tax withholding, she directly beneficially owns 67,469 shares of Emergent BioSolutions common stock.
Emergent BioSolutions executive Coleen Glessner reported equity award outcomes and related share movements. On February 6, 2026, she recorded a disposition of 28,847 shares of common stock at $10.92 per share linked to performance stock units granted under the company’s stock incentive plan.
The Compensation Committee certified the 2023–2025 performance stock units at 25% of target, resulting in an actual award of 9,615 shares of common stock, compared with 38,462 shares previously reported for that grant. She also had 2,852 shares withheld at $10.92 per share to cover taxes on vesting and settlement of restricted stock units.
Following these transactions, Glessner directly beneficially owns 112,620 shares of Emergent BioSolutions common stock.
Emergent BioSolutions SVP Paul Anthony Williams reported equity compensation outcomes and share movements. On February 6, 2026, he reported a disposition of 8,655 shares of common stock at $10.92 per share, leaving him with 77,216 shares directly held, then a further 1,022 shares were withheld at $10.92 to cover taxes tied to restricted stock unit vesting, resulting in 76,194 shares owned afterward.
The filing explains that these transactions relate to performance stock units granted under the company’s stock incentive plan. The compensation committee certified 2023–2025 PSU performance at 25% of target, leading to an actual award of 2,884 shares of common stock, below the 11,539 shares previously reported for that award cycle.
Emergent BioSolutions SVP, Bioservices William Hartzel reported routine equity award adjustments and tax withholding transactions in company stock. On February 6, 2026, 5,771 performance stock units tied to 2023–2025 goals were disposed of after the Compensation Committee certified performance at 25% of target, resulting in a smaller share payout than originally reported.
On the same date, 630 shares of common stock were withheld to cover taxes on vested restricted stock units. After these transactions, Hartzel directly owned 96,681 shares of Emergent BioSolutions common stock.
Emergent BioSolutions EVP and CFO Richard S. Lindahl reported equity award activity tied to performance stock units and tax withholding. On February 6, 2026, he disposed of 46,155 shares of common stock at $10.92 per share and had 245,342 shares beneficially owned immediately afterward.
The filing explains that 2023–2025 performance stock units under the company’s stock incentive plan were certified at 25% of target, resulting in an actual award of 15,384 shares of common stock. In a separate transaction the same day, 5,642 shares at $10.92 per share were withheld to cover taxes on vesting, leaving Lindahl with 239,700 directly owned shares.